Development of a Novel Whole Genome Sequencing-based Platform for Rapid Identification and Antimicrobial Profiling of Uropathogens
Award amount
$303,932Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DAY ZERO DIAGNOSTICS INC
- Proposal award date
- 2022-06-01
- Contract end date
- 2022-09-30
- UEI
- KZKSJLYEAE83
- Solicitation number
- PA20-260
- Topic code
- R
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- EpiXact-FMT: A metagenomic, pharmacovigilance assay for microbiota therapeutics safety
- Next-day whole genome sequencing and analysis using nanopore sequencing for real-time outbreak and transmission determination in healthcare facilities
- Automated algorithm for rapid, scalable determination of hospital acquired bacterial infections using whole genome sequencing
Research funding history
4 SBIR/STTR records share this UEI (2019–2023). Reported award amounts total $1,128,365. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services